FDA Rejects Piziotinib for Certain Types of NSCLC

The drug was not approved for the treatment of patients with previously treated locally advanced or metastatic nonsmall cell lung cancer harboring HER2 exon 20 insertion mutations.
Medscape Medical News

source https://www.medscape.com/viewarticle/984604?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?